ARDX
Ardelyx, Inc.
NASDAQ · USHealthcareBiotechnology
$5.09-2.12%
Price as of Jul 20, 2026
ARDX financials
Ardelyx, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $407.3M | $333.6M | $124.5M | $52.2M |
| Cost of revenue | $42.6M | $50.6M | $17.8M | $4.1M |
| Gross profit | $364.7M | $283.1M | $106.7M | $48.0M |
| Operating expenses | $405.7M | $311.0M | $169.9M | $111.8M |
| Operating income | -$41.0M | -$27.9M | -$63.3M | -$63.8M |
| Net income | -$61.6M | -$39.1M | -$66.1M | -$67.2M |
| EBITDA | -$29.2M | -$16.7M | -$55.4M | -$61.0M |
| Basic EPS | $-0.26 | $-0.17 | $-0.30 | $-0.42 |
| Diluted EPS | $-0.26 | $-0.17 | $-0.30 | $-0.42 |
| Balance sheet | ||||
| Cash & equivalents | $68.0M | $64.9M | $21.5M | $96.1M |
| Total assets | $501.6M | $435.8M | $297.6M | $190.1M |
| Total liabilities | $334.7M | $262.5M | $130.8M | $91.7M |
| Stockholders’ equity | $166.9M | $173.3M | $166.8M | $98.3M |
| Total debt | $211.6M | $153.4M | $56.0M | $36.5M |
| Net debt | $143.6M | $88.5M | $34.5M | -$59.7M |
| Cash flow | ||||
| Operating cash flow | -$42.5M | -$44.8M | -$89.7M | -$70.0M |
| Capital expenditure | -$1.5M | -$1.0M | -$344.0K | -$55.0K |
| Free cash flow | -$44.0M | -$45.8M | -$90.1M | -$70.1M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |